Oragenics Announces Award Of A Grant From CQDM For Development Of A Variant-Agnostic Protein Antigen For Use In Its COVID-19 Intranasal Vaccine Receives
Portfolio Pulse from Benzinga Newsdesk
Oragenics has been awarded a grant from CQDM for the development of a variant-agnostic protein antigen for use in its COVID-19 intranasal vaccine.
June 05, 2023 | 8:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oragenics receives a grant from CQDM for the development of a variant-agnostic protein antigen for its COVID-19 intranasal vaccine, potentially boosting its vaccine development.
The grant from CQDM will provide Oragenics with additional funding for the development of its COVID-19 intranasal vaccine. This could potentially accelerate the development process and increase the chances of success, which would positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100